Cerenome Secures National In-Network Agreement with Aetna for CNSide®

Cerenome secures Aetna deal, expanding CNSide’s coverage to 190 million lives nationwide.

What the company is saying

Cerenome, through its subsidiary CNSide Diagnostics, is announcing a national in-network laboratory ancillary provider agreement with Aetna Health Plans, effective November 1, 2026. The company frames this as the first national CNSide payer agreement to cover both tumor cell enumeration and molecular profiling, emphasizing the expansion of contracted reimbursement for its CNSide CSF diagnostic tests. The release highlights that the Aetna agreement adds approximately 26 million medical members, bringing total in-network coverage to about 190 million lives. Marc Hedrick, M.D., President and CEO, is quoted to underscore the intent to replicate this model with other payers, aiming to secure broad payment pathways for CNSide’s key diagnostics. The announcement stresses the clinical validation of CNSide’s tests, referencing a peer-reviewed study of 1,391 CSF specimens and 12 supporting publications, as well as operational traction with over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020. The tone is confident, focusing on commercial momentum and scientific credibility, while forward-looking statements are limited to intentions for further payer expansion.

What the data suggests

The agreement with Aetna is effective immediately, as of November 1, 2026, and increases CNSide’s contracted payer footprint by 26 million, to a total of approximately 190 million covered lives. This represents a significant expansion in market access for CNSide’s CSF Tumor Cell Enumeration and Molecular Profile tests. The operational data show that since 2020, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions, indicating growing clinical adoption. The molecular profiling approach has been validated in a peer-reviewed study of 1,391 CSF specimens, and the utility of tumor cell analysis is supported by 12 publications and multicenter trial evidence. While the announcement provides robust figures for coverage and test adoption, it does not disclose revenue, reimbursement rates, or profitability metrics tied to the Aetna agreement. The evidence supports a narrative of expanding payer access and clinical validation, but leaves the direct financial impact unquantified.

Analysis

The announcement is largely factual and proportionate to the disclosed achievements. The core claims—entry into a national in-network agreement with Aetna, the addition of 26 million covered lives, and a total contracted footprint of 190 million—are all supported by specific numerical data and effective dates. The operational scale is further substantiated by test volumes and institutional adoption figures. Only a single forward-looking statement is present, regarding the intent to pursue similar agreements, which is clearly separated from realised milestones. There is no evidence of exaggerated language or narrative inflation; the tone is positive but not promotional. No large capital outlay or long-dated, uncertain returns are discussed, and the benefits of the Aetna agreement are immediate with the effective date already reached. The absence of profitability or revenue metrics limits the signal to weak_positive, as per the Disclosure Completeness Rule.

Risk flags

• ●The announcement does not disclose reimbursement rates or expected revenue from the Aetna agreement, making it difficult to assess the financial impact or margin contribution of the expanded coverage. This limits visibility into the agreement’s bottom-line effect.
• ●Clinical adoption is evidenced by 11,000 tests since 2020, but future growth depends on continued physician uptake and payer utilization, which may be influenced by factors such as competing diagnostics, changes in clinical guidelines, or payer policies.
• ●While the peer-reviewed validation and multicenter evidence support the clinical utility of CNSide’s tests, the company’s ability to replicate similar agreements with other major payers remains an aspirational goal and is not guaranteed by this announcement.

Bottom line

Cerenome’s national agreement with Aetna immediately expands CNSide’s contracted coverage to approximately 190 million lives, positioning the company for broader clinical and commercial reach. The announcement is backed by concrete figures for payer footprint and operational test volumes, and clinical validation is supported by peer-reviewed studies and multicenter evidence. However, the absence of disclosed reimbursement rates or revenue projections means the direct financial benefit remains unclear. The company’s stated intent to pursue similar deals with other payers is forward-looking and not yet realized. Investors should focus on future disclosures of revenue growth, payer utilization rates, and additional national agreements as the next indicators of commercial traction. The most important takeaway is that CNSide’s payer access has materially expanded, but the financial upside will depend on execution and market adoption.

Announcement summary

(NASDAQ:CNSY) Cerenome, Inc., through its wholly-owned subsidiary CNSide Diagnostics, LLC, announced it has entered into a national in-network laboratory ancillary provider agreement with Aetna Health Plans, Inc., effective November 1, 2026. This agreement establishes contracted reimbursement for both the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test and CNSide® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. The Aetna agreement is the first national CNSide payer agreement to include both tumor cell enumeration and molecular profiling. With this agreement, approximately 26 million Aetna medical members are added to CNSide’s contracted payer footprint. Including previously announced payer agreements, CNSide now has in-network agreements representing approximately 190 million covered lives. Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome, stated that the company intends to pursue similar arrangements across its entire payer base to secure payment pathways for its critical diagnostic tests. The Aetna agreement provides contracted reimbursement for CNSide® CSF Tumor Cell Enumeration, CNSide® CSF Molecular Profile – Solid Tumor, and CNSide® CSF Molecular Profile – Hematologic Malignancy. The Molecular Profile tests offer DNA and RNA molecular profiling of CSF for patients with suspected or confirmed primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS. The DNA and RNA CSF molecular profiling approach was recently evaluated in a peer-reviewed, real-world study of 1,391 evaluable CSF specimens, published in The Journal of Liquid Biopsy. The clinical utility of CNSide CSF tumor cell analysis in leptomeningeal metastases is supported by 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. Since 2020, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions. Aetna, a CVS Health business, serves an estimated 37 million people with a range of health insurance products and services. CNSide Diagnostics, LLC develops and commercializes CSF-based diagnostic tests for cancers involving the central nervous system, offering both tumor cell enumeration and molecular profile tests. Cerenome is advancing an integrated CNS oncology platform combining diagnostics, therapeutics, and artificial intelligence, with its lead therapeutic platform REYOBIQ™ (rhenium Re186 obisbemeda) in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers.

Disagree with this article?